The impact of immigration and vaccination in reducing the incidence of hepatitis B in Catalonia (Spain) by Oviedo de La Fuente, Manuel et al.
Oviedo et al. BMC Public Health 2012, 12:614
http://www.biomedcentral.com/1471-2458/12/614RESEARCH ARTICLE Open AccessThe impact of immigration and vaccination in
reducing the incidence of hepatitis B in Catalonia
(Spain)
Manuel Oviedo1,2, M Pilar Muñoz2,3*, Gloria Carmona4, Eva Borrás2,4, Joan Batalla2,4, Nuria Soldevila2
and Angela Domínguez2,5Abstract
Background: The Hepatitis B virus (HBV) infection is a major cause of liver disease and liver cancer worldwide
according to the World Health Organization. Following acute HBV infection, 1-5% of infected healthy adults and up
to 90% of infected infants become chronic carriers and have an increased risk of cirrhosis and primary
hepatocellular carcinoma. The aim of this study was to investigate the relationship between the reduction in acute
hepatitis B incidence and the universal vaccination programme in preadolescents in Catalonia (Spain), taking
population changes into account, and to construct a model to forecast the future incidence of cases that permits
the best preventive strategy to be adopted.
Methods: Reported acute hepatitis B incidence in Catalonia according to age, gender, vaccination coverage,
percentage of immigrants and the year of report of cases was analysed. A statistical analysis was made using three
models: generalized linear models (GLM) with Poisson or negative binomial distribution and a generalized additive
model (GAM).
Results: The higher the vaccination coverage, the lower the reported incidence of hepatitis B (p <0.01). In groups
with vaccination coverage > 70%, the reduction in incidence was 2-fold higher than in groups with a coverage
<70% (p <0.01). The increase in incidence was significantly-higher in groups with a high percentage of immigrants
and more than 15% (p <0.01) in immigrant males of working age (19-49 years).
Conclusions: The results of the adjusted models in this study confirm that the global incidence of hepatitis B has
declined in Catalonia after the introduction of the universal preadolescent vaccination programme, but the
incidence increased in male immigrants of working age. Given the potential severity of hepatitis B for the health of
individuals and for the community, universal vaccination programmes should continue and programmes in risk
groups, especially immigrants, should be strengthened.
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tocellular carcinoma. HBV is carried in the blood and
other body fluid [1], including saliva, tears, semen and
vaginal secretions, and person-to-person transmission
is possible by various means, depending on the epide-
miologic pattern within a geographic area [2]. In areas
of high endemicity, the most common routes of infec-
tion are vertical mother-child transmission and hori-
zontal transmission between children, particularly
siblings. In areas of intermediate or low endemicity,
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Currently, hepatitis B is considered a major health
problem, not only by health professionals, but also by
many areas of society, especially sufferers [3] and the
elevated health costs of the disease have been high-
lighted [4].
Safe, effective vaccines have been available to prevent
hepatitis B virus infection since 1981 and the cost-
effectiveness of hepatitis B vaccination programmes is
well documented [5]. Recently, some recommendations
on the identification and management of persons with
chronic hepatitis B virus infection have been proposed
[6,7], but vaccination is regarded as the best strategy
to diminish the disease burden. In Catalonia, hepatitis
B vaccination programmes began in 1984 with a vac-
cine obtained from human plasma that was expensive
and had limited availability. Vaccination was carried out
in groups at risk of suffering the disease due to lifestyles
or work exposure and in newborns of mothers who were
carriers of the virus, in accordance with the recommen-
dations in place at that time. Unfortunately, this strategy
had a limited impact on the incidence and long-term
consequences of the disease, and highlighted the need
for a strategy of universal vaccination in order to suc-
cessfully prevent the disease. The availability of an
effective, safe and cheaper vaccine obtained by genetic
recombination opened the way for mass vaccination pro-
grammes to protect the whole population [8]. In Decem-
ber 1990, the Department of Health of Catalonia, after
analyzing the available data on the impact obtained in
terms of vaccination coverage and reduction of disease
incidence with the vaccination programmes aimed at
risk groups, decided to adopt a strategy of universal vac-
cination of preadolescents in schools, in addition to the
vaccination of newborns from infected mothers and high
risk groups [9]. In 2002, the Department of Health intro-
duced the vaccination of newborns at 2, 4, and 6 months
without abandoning the vaccination of preadolescents,
which was of proven benefit [10]. This strategy, main-
tained until the first cohort of infants reached the age at
which they could have been offered the preadolescent
programme, seems to be the most comprehensive ap-
proach [1].
Infectious disease models have been proposed to esti-
mate the burden of hepatitis B infection, and the impact
of vaccination [11,12], in order to develop disease con-
trol strategies [13,14].
The aim of this study was to investigate the relation-
ship between the reduction in acute hepatitis B inci-
dence and the universal vaccination programme of
preadolescents in Catalonia, taking population changes
into account, and to construct a model to forecast the
future incidence of cases that permits the best prevent-
ive strategy to be adopted.Methods
Study population
The study was conducted in Catalonia, a region of more
than 7 million inhabitants in Northeast Spain. All acute
cases of hepatitis B reported to the Department of
Health of the Generalitat of Catalonia from 1992 to
2007 (n = 2325) were included in the study. An acute
case of hepatitis B was considered as an acute illness
with a discrete onset of symptoms and jaundice or ele-
vated serum aminotransferase that presented IgM
against hepatitis B core antigen (anti-HBc) or hepatitis B
surface antigen and negativity for markers of other hepa-
titis viruses. For the years 2005 to 2007, the country of
origin of 74.2% of reported cases (n = 473) was known.
In this period, 51% of the cases occurred in indigenous
subjects and 49% in immigrants.
The study included the incidence of disease by age,
gender, vaccination coverage, percentage of immigrants
and year of report of the disease.
The population of Catalonia was obtained from the
2007 Catalan census (IDESCAT) [15]. The percentage of
subjects born outside Spain was estimated by linear
interpolation for the years in which data were not avail-
able (1992-1995 and 1997-1999).
Because the study was carried out with data reported
by the Statutory Reporting System of the Department of
the Generalitat of Catalonia without identification of the
subjects, it was not necessary to be present it to the
Ethics committee. All data used in this study are publicly
available.
Statistical methods
Generalized linear model (GLM) and generalized additive
model (GAM)
The statistical analysis was performed using the R statis-
tical package, version 2.10.1 (http://cran.r-project.org)
Three models were used to adjust the incidence of
hepatitis B: a generalized linear model (GLM) [16] with
either Poisson or negative binomial distribution [17] and
a generalized additive model (GAM) [18].
To determine which model best fit the incidence data,
we estimated whether there was overdispersion in the
data [19]. As the effect of continuous covariates may be
non-linear, we made a nonparametric estimate using the
smoothing techniques of the GAM model.
We made a new adjustment of the GLM and GAM
models for the period 2000-2007 incorporating gender
as a predictive variable. This was only possible from
2000 onwards, when the percentage of immigrants
according to gender in the age group included in the
study could be calculated.
The relationship between the response variable and
the covariates was detected by studying the main effects
and their interactions. The interactions were specified by
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includes interactions among the covariates. The best
model was considered that with the minimum AIC
(Akaike information criterion) and we compared the dif-
ferent adjusted models using the Anova test. Statistical
significance was set assuming an α error = 0.05.
Study variables
Dependent variables
Confirmed cases of hepatitis B in Catalonia (cases).
Independent variables or covariates
The covariates included in the model were: the year of
report (year), vaccination coverage (vac), the percentage
of the population born outside Spain (immigrant) and
age (age), which was aggregated in six categories:
age ¼
ref for age < 12 years
1 for 12≤ age < 19 years
2 for 19≤ age < 34 years
3 for 35≤ age < 49 years
4 for 50≤ age < 59 years
5 for age ≥60 years
8>>><
>>>:
Adjusted models
All the models presented below contain the interaction,
calculated as the product of two covariates; however
they have not been included in the equations for the
sake of simplicity.
Generalized linear models glm.pois1 and glm.nb1 (see
eq.1) were used to estimate the incidence of hepatitis B
in Catalonia adjusted by year, age, vac, immigrant and
population as an offset parameter under the Poisson and
negative binomial distributions, respectively.
log casesð Þ ¼ β0 þ β1year þ β2;...;6ageþ β7vac
þ β8imnmigrant þ log populationð Þ þ E ð1Þ
The GAM gam1 (see eq.2) uses smoothing of the
continuous variables (year, vac and immigrant), denoted
by s(year), s(vac) and s(immigrant), respectively, and
Poisson probability distribution, to adjust the incidence
of hepatitis B:
log casesð Þ ¼ β0 þ βyears yearð Þ þ β2;...6age
þ β vars vacð Þ
þ βimmnimgrants immigrantð Þ
þ log populationð Þ þ E ð2Þ
The model in equation 1 was modified by substituting
the variable vac by three categories:
vac∗ ¼
ref for coverage vaccination ¼ 0%
1 for 0 < coverage vaccination < 70%
2 for coverage vaccination≥70%
8<
:and substituting the variable immigrant by four categories:
immigrant ¼
ref for immigration rate < 5%
1 for 5%≤ immigration rate < 10%
2 for 10%≤ immigration rate < 15%
3 for immigration rate ≥15%
8>><
>:
resulting in GLMs glm.pois2 and glm.nb2, which were
adjusted according to equation 3. The coefficients asso-
ciated with the variables age, vac* and immigrant * in eq.3
are represented by a single parameter, but with several
sub-indices, because these variables are categorical and
they need as many coefficients as categories:
log casesð Þ ¼ β0 þ β1year  þβ2;...;6ageþ β7;8vac
þβ9;10;11immigrant
þ log populationð Þ þ E ð3Þ
Equation 4 shows the model for the years 2000-2007
in which the models from equation 1 were adjusted
using Poisson and negative binomial, respectively, and
the variable gender was also included. In this case, only
the variables age and gender are categorical:
gender ¼ ref for females
1 for males

log casesð Þ ¼ β0 þ β1year þ β2;...;6ageþ β7vac
þ β8imnmigrant þ β9gender
þ log populationð Þ þ E ð4Þ
Finally, we estimated the incidence of hepatitis B using
the GAM gam1 * model in which continuous variables
from equation 3 were adjusted by smoothing. Model
gam2* was obtained by adding the estimate of the
variable gender to model gam1* (see eq.5). In both
cases, the probability distribution of errors was a Pois-
son distribution.
log casesð Þ ¼ β0 þ βyears yearð Þ þ β2;...;6age
þ β vars vacð Þ
þ βinmnimgrants immigrantð Þ
þ β9gender þ log populationð Þ þ E ð5Þ
Forecasting models and sensitivity analysis
The prediction of the incidence of hepatitis B was made
using the adjusted models, and new data on the cova-
riables, such as the number and percentage of immi-
grants according to age and sex, was necessary. The pro-
jections of these covariables were obtained from data
provided by IDESCAT. However, the future percentage
of the population vaccinated is not known a priori, and
therefore various scenarios that allow different percen-
tages of vaccination are necessary. For example, one
possible scenario is to assume that the percentage of
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Other possible scenarios could be that the percentage of
vaccination remains constant while supposing an in-
crease in the incidence or in the proportion of immi-
grants in the age and sex groups, or that vaccination of
some risk group could be considered. This study was
concentrated on the prediction of vaccination in 2008
and 2009, assuming a constant annual increase of 5% in
vaccination.
Results
For the period 1992-2007, the estimated coefficients of
the variables year, age, vac and immigration were signifi-
cant in all adjusted models (eq.1, 2 and 3). Table 1 shows
the results of the best adjusted generalized models, the
GLM models using negative binomial distribution: glm.
nb1 and glm.nb2, and GAM gam1. In all models, the an-
nual incidence decreased significantly (p-value <0.001).
The best fit was achieved with the gam1 model
described in equation 2, (AIC= 593).
Model gam1 shows whether the trend of the variables
was linear or not. Reporting of hepatitis B cases
decreased over time until 2001, as indicated by the esti-
mated smoothing coefficient of the variable year and its
graphic representation (Figure 1A). From 2001 to 2004,
there was an increase in the incidence of hepatitis B
infection.Table 1 Estimates of generalized linear models (glm.nb1 and
period 1992-2007
Model glm.nb1
Coefficients: Estimate Pr(>|z|)
Intercept 136.99 <0.001
Year (continuous) −0.075 <0.001
Age<12 y Ref. -
12-18 y 1.196 <0.001
19-34 y 1.515 <0.001
35-49 y 1.083 <0.001
50-59 y 1.024 <0.001
> 59 y 0.420 0.015
Vac (continuous) −1.926 <0.001
Immigrant (continuous) 6.404 <0.001
Vac= 0% - -
0%<vac< 70% - -
vac >=70% - -
Immigrant < 5% - -
5%< immigration < 10% - -
10%< immigration < 15% - -
immigration > 15% - -
AIC 622In the adjusted GLM models (glm.nb1 and glm.nb2 in
Table 1) the incidence was higher in all age groups (age)
for children under 12 years (p <0.001) but was less pro-
nounced for people aged > 59 years (p = 0.015).
The percentage of vaccination was significant (p <0.001)
in the glm.nb1 model; the higher the rate of vaccin-
ation, the lower the incidence. In model gam1, vaccin-
ation coverage (vac) was introduced non-parametrically
s(vac) and was significant (p <0.001). The trend was
nonlinear and negative (Figure 1B), i.e., vaccination re-
duced cases of hepatitis B, and the greatest slope at the
origin more clearly separates the vaccinated groups
(with lower incidence) from unvaccinated groups.
Model glm.nb2 , which collected the categorization of
vaccination coverage and the rate of immigration, can
be considered as an alternative model to model glm.nb1
(p <0.05), as confirmed by the ANOVA test, meaning
there were no significant differences between models
glm.nb1 and glm.nb2.
Model glm.nb2 shows that when the vaccination
coverage was > 70% there was a two-fold higher reduc-
tion in incidence compared with vaccination coverages
< 70% (Table 1). The opposite occurred with the percent-
age of immigration (model gam1 ). The percentage of
immigration showed a non-linear but positive trend
(Figure 1C). The slope was steeper from a rate of 15%
indicating that the greater the percentage of immigration,glm.nb2) and additive models (gam1) for the study
Model gam1 Model glm.nb2
Estimate Pr(>|z|) Estimate Pr(>|z|)
158.695 <0.001 80.771 <0.001
−0.085 <0.001 −0.046 <0.001
Ref. - -Ref. -
1.291 <0.001 1.192 <0.001
1.595 <0.001 1.721 <0.001
1.076 <0.001 1.171 <0.001
1.028 <0.001 0.987 <0.001
0.461 <0.001 0.335 0.015
−2.297 <0.001 - -
7.144 <0.001 - -
- - Ref. -
- - -.0700 <0.001
- - −1.51 <0.001
- - Ref. -
- - 0.159 0.307
- - 0.118 0.587
- - 0.761 <0.001
593 625
Figure 1 The number of cases of hepatitis B have been modelled as smooth functions of year of report (year), vaccination coverage
(vac) and proportion of immigrants (percen), using a GAM model. Results for the gam1 model (period 1992-2007) are on the left panel and
on the right panel, those for gam* model (period 2000-2007). The x axis of each plot is labelled with the covariate name and the y axis is labelled
s(cov,edf) where cov is the covariate name, and edf the degrees of freedom of the smooth function. Upper and lower pointwise
twice-standard-error curves are included (dashed lines).
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rate between 5% and 10% or between 10% and 15% did
not have a greater incidence than when the percentage
is < 5% (p = 0.307 and p = 0.587, respectively), while for a
percentage of immigration of >15%, the increase in inci-
dence was significantly higher than in groups with a per-
centage of immigration of<5% (p <0.001) (Table 1).
We identified the presence of four outliers, corre-
sponding to the <12 years age group in 1998, 2001 and
2002, in whom the incidence was higher than estimated,
and adolescents aged 12-18 years in 2000, with zero inci-
dence. The residuals of the adjusted model were consid-
ered valid, and this model was proposed to explain and
forecast the reported incidence of the disease.
Figure 2 panel (c) shows the temporal distribution of
hepatitis B infection according to gender in the
19- 49 years age group (all ages group), which had the
highest incidence, varying from> 8 x10-5 person-years in
males and 3 x10-5 person-years in females in 1992 and
1993 to 1.8 x 10-5 person-years in males and 0.65 x10-5
person-years in females in 2001. However, from 2001 on-
wards, the incidence increased in males aged 19-49 years,
reaching 6.7 x10-5 person-years in 2006, with a slight in-
crease in females in the same age group to nearly 1.5
x10-5 person-years. The rate observed in the 19-34 years
age group [Figure 2 panel (a)] declined until 2001 and
then, despite the increase in vaccination coverage, rose
again. The distribution of cases in the 35-49 years age
[Figure 2, panel (b)] was similar from 2001 onwards, to
the observed 19-34 years group. The proportion of immi-
grants increased over time (green line) and the increase
was much greater from the year 2000 onwards.
The male/female ratio in incidence rates fluctuated be-
tween 3 and 4 x10-5 person-years, except in 2003, when
six cases were reported in males aged 19-49 years for
each case reported in women of the same age. The rates
were less than for the total population, passing from
4 x 10-5 person-years in males and 2 x10-5 person-years
in females in 1992 to 1.2 in males and 0.5 in females
in 2001; in 2007 the rates rose to 3 x 10-5 person-years in
males and 0.8 x10-5 person-years in females. The male/
female ratio increased over time, from 2 reported cases
reported in males for each case in females in 1992 to al-
most 4 reported cases in males for each case in females
in 2007.
Incidence rates for children aged < 12 years were below
2 x10-5 person-years and there were 4 cases, all immi-
grants, in the last year, 2007. As vaccination coverages
rose in the 12-18 years age group, the reported incidence
rate fell until 1995 and remained low (<1 x10-5 person-
years) until 2007.
The variable gender was incorporated into the re-
gression models for the period 2000-2007, when the pro-
portion of immigrants could be calculated according togender, year and age. Table 2 shows the results of dif-
ferent models with and without the inclusion of the
variable gender. Once again, the models with negative
binomial distribution had a lower AIC and therefore a
better estimate than the models which assumed a
Poisson distribution. The inclusion of the variable gen-
der always improved estimates (ANOVA test: p <0.001).
Model glm.nb1* (eq.1) had an AIC of 554, while the
model using negative binomial distribution including
gender had an AIC of 485 (model glm.nb3, eq.4). In the
GAM models, the AIC passed from 604 in model gam1*
(eq.2) to 487 in model gam2 * (eq.5). Models glm.nb3*
and gam2* showed similar results: in both cases the esti-
mate of the variable year was not significant (p > 0.05).
As shown in Figure 1D, smoothing by year in the gam2 *
model can be assimilated to the trend remaining ap-
proximately constant throughout the study period.
The significance of the percentage of vaccination was
greater for model gam2* than for model glm.nb3*
(p = 0.009 and p = 0.05, respectively), and the trend
remained negative and nonlinear (Figure 1E). The per-
centage of immigration was significant in both models
(p <0.01) and the trend remained positive and nonlinear
(Figure 1F). The inclusion of gender in the models
allowed a better fit, and the estimated coefficients of the
variable gender in both models were similar and signifi-
cant (p <0.01 and p <0.001 respectively, Table 2).
The residuals for the GLM and GAM models for the
period 2000-2007 (eq. 1, 4, 2 and 5, respectively) were
also considered correct. Interactions between gender and
other covariates (age, and/or year, vac or immigration)
were not significant.
The percentage of cases that occurred in immigrants
during the 2005-2007 period decreased with age; 91% in
immigrant children aged < 12 years, 82% in immigrants
aged 12-18 years, 61% in young adults and only 14.5% in
immigrants aged > 50 years. As shown in Figure 3, this
means that the ratio between the incidence rate in immi-
grants and in indigenous persons was higher in children
aged < 12 years (ratio = 77.2, rate of 3.86 x10-5 person-
years in immigrant children compared to 0.05 x10-5
person-years in indigenous children) and in people aged
12- 18 years (ratio = 23.19, rate of 3.7 x10-5 person-years
compared to 0.2 x10-5 person-years in indigenous
children).
Figure 4 shows the distribution of the incidence in
immigrants according to gender and age group for
the period 2005-2007. The incidence rate for male
immigrants was > 5 in all age groups except
the > 59 years age group. In people aged < 18 years,
the origin (born in Spain or outside) was known in
18 of the 21 cases (86%). In immigrant girls, the inci-
dence rate was around 2.36 x10-5 person-years and in
boys it was more than double, at 5.3 x10-5 person-years
Figure 2 Incidence rate by gender and percentage of immigrants in Catalonia. Males in blue, females in red and % immigration in green.
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Table 2 Estimates of models glm.nb1*, glm.nb3*, gam1* y gam2* for the study period 2000-2007
Model glm.nb1* Model glm.nb3* Model gam1* Model gam2*
Coefficients: Estimate Pr(>|z|) Estimate Pr(>|z|) Estimate Pr(>|z|) Estimate Pr(>|z|)
Intercept 245.03 0.024 82.95 0.280 376.20 <0.001 −7.39 0.916
Year (continuous) −0.13 0.018 −0.05 0.214 −0.19 <0.001 −0.002 0.941
Age<12 y Ref. - Ref. - - - Ref. -
12-18 y 2.95 0.0267 1.37 0.074 4.96 <0.001 1.70 0.011
19-34 y 0.84 0.039 0.87 <0.001 1.28 <0.001 1.27 <0.001
35-49 y 0.15 0.627 0.56 0.015 −0.013 0.945 0.76 <0.001
50-59Y 0.96 <0.001 0.91 <0.001 1.01 <0.001 0.84 <0.001
> 59Y 0.57 0.039 0.35 0.09 0.70 <0.001 0.09 0.612
Vac (continuous) −3.80 0.016 −1.74 0.050 −6.40 <0.001 −2.03 0.009
Immigrant (continuous) 3.57 <0.001 8.11 <0.01 20.39 <0.001 5.44 0.008
Gender - - 0.88 <0.01 - - 0.89 <0.001
AIC 554 485 604 487
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aged < 19 years was <0.2 person-years in both males and
females, but was 5.55 x10-5 person-years in immigrant
males aged < 19 years, much higher than the nearly 2
x10-5 person-years in immigrant females of the same
age (p <0.001).
Tables 3 and 4 show the results of the prediction for the
models described in Tables 1 and 2, respectively, assuming
a constant increase of 5% in vaccination in 2008 and 2009.
The gam models were clearly the best models for the pre-
diction, as they were those which best adjust the non-
lineal behaviour of the temporal evolution of the incidence
of hepatitis B. The gam2 model (Table 3) estimated inci-
dence rates of 1.76 (95% CI: 1.62-1.90) and 1.54 (95% CI:Figure 3 Ratio (immigrant/indigenous) of the incidence rate per 100,0
2005-2007.1.41-1.67) for 2008 and 2009, respectively, compared with
the 1.68 and 1.63 observed in 2008 and 2009, respectively.
In 2008 (Table 4) the gam2* model estimated an incidence
rate of 0.98 (95% CI: 0.87-1.11) compared with the
observed rate of 1.00: likewise, the estimate was 0.89 (95%
CI: 0.78-1.011) in 2009, compared with an observed rate
of 0.93. In males, the incidence rate is overestimated in
2008 (3.03 (95% CI: 2.72-3.38)) compared with the
observed rate of 2.38. In 2009, the observed rate was 2.38,
compared with the estimated rate of 2.69 (95% CI: 2.38-
3.04). As in the estimate, the prediction is better when the
variable gender is included in the model, although it is
slightly worse for the gam1* model and better results are
obtained for the gam2* model.00 population per year and cases of hepatitis B in Catalonia
Figure 4 Incidence rate in Catalonia 2005-2007 according to: age group (y axis), gender (dark orange) for females and (pale orange)
for males and nationality (left panel) for indigenous subjects and (right panel) immigrants.
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As with any vaccine-preventable disease, hepatitis B
vaccination programmes should be reviewed according
to the evolution of the disease, and surveillance data
are crucial to enable correct assessments of the situ-
ation [1].
The results of our study are consistent with those for
hepatitis A, which showed that the estimates of GLM
using negative binomial distribution were better [19]. In
addition, GAM permitted estimation of non-linear
trends of continuous variables as year, vac and immi-
grant. The incidence of hepatitis B fell from 1992 to
2000, and has since increased non-linearly, being much
higher in groups with a high percentage of immigration
and falling when vaccination coverages are higher.
The results also coincide in the case of categorical
variables in the GLM models. Poisson or negative bino-
mial regression can cause problems in estimating the
coefficients due to the low incidence of cases. This is a
limitation of the model that was solved by aggregation
into age groups, and not introducing it as a continuous
variable. An alternative would have been to adjust using
models for count data with Poisson distribution with
many zeros (ZIP) or negative binomial (ZINB) [20].
With respect to the predictions, future studies could
simulate the predictions of future incidence rates with
vaccination strategies other than those proposed in thisTable 3 Incidence predicted and 95% confidence predicted in
Year Incidence Observed Incidence predicted by model glm.nb1
2008 1.68 1.94 (1.69-2.39)
2009 1.63 1.94 (1.66-2.26)study. This could allow evaluation of these strategies and
the detection of atypical incidence rates other than the
estimated pattern.
The use of two data sets (1992-2007) and (2000-2007,
which included the category male/female, has advan-
tages and disadvantages. Using the (1992-2007) data-
base has the advantage of a 16-year historical record in
which the estimated coefficient of the variable year is
significant. This is one possible explanation of why the
estimates are better using this database. In the second
case, the use of the (2000-2007) database supposes a
historical record of only eight years. The positive aspect
is that the clearly-differentiated incidence rates in males
and females can be estimated. However, the estimated
coefficient of the variable year is not significant in this
period in the models with the lower AIC (glm.nb3 y
gam2). As the number of observations is reduced, the
number of degrees of freedom and, therefore, the esti-
mates, are worse.
La Torre et al. [12], applied jointpoint regression and
estimated that the incidence decreased in all groups, and
highlighted the importance of analyzing the changes in
disease incidence in the evaluation of vaccination policies.
The increased incidence in men aged 19-49 years from
2001 onwards obtained in the present study with the over-
all rate increasing from 2.16 in 2000 to 5.74 in 2007(x10-5
person-years) respectively, coincides with the mass influxterval (CI) by year for models in Table 1
Incidence predicted by model gam1 Incidence predicted by gam2
1.88 (1.64-2.15) 1.76 (1.62-1.90)
1.79 (1.56-2.05) 1.54 (1.41-1.67)
Table 4 Incidence predicted and 95% confidence predicted interval (CI) by year and gender for models in Table 2
Year Gender Incidence Observed Incidence
predicted by
model glm.nb1*
Incidence
predicted by
model glm.nb3*
Incidence
predicted by
gam1*
Incidence
predicted by
gam2*
Females 1.00 2.06 (1.68-2.53) 1.31 (1.16-1.47) 1.33 (1.17-1.50) 0.98 (0.87-1.11)
2008 Males 2.38 3.27 (2.61-4.11) 4.08 (3.65-4.59) 3.98 (3.55-4.46) 3.03 (2.72-3.38)
All 1.68 2.66 (2.14-3.31) 2.68 (2.40-3.01) 2.65 (2.36-2.97) 2.00 (1.79-2.24)
Females 0.93 2.17 (1.73-2.71) 1.37 (1.21-1.57) 1.40 (1.23-1.60) 0.89 (0.78-1.01)
2009 Males 2.34 3.43 (2.68-4.40) 4.27 (3.78-4.83) 4.19 (3.69-4.76) 2.69 (2.38-3.04)
All 1.63 2.80 (2.02-3.55) 2.81 (2.48-3.19) 2.79 (2.45-3.17) 1.78 (1.57-2.02)
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22.7% in 2007 [15]; in this same period, the incidence in
men aged 19-34 years increased from 2.9 in 2000 to 5.3 in
2007 (x10-5 person-years) and in men aged 35-49 years
from 1.4 in 2000 to 7.5 in 2007 (x10-5 person-years).
These results differ from those obtained in the USA
[21,22], where the incidence rate of hepatitis B has de-
creased steadily in all age groups, from 6.3 x 10-5 person-
years in 1992 to 1.5 x10-5 person-years in 2007. In that
country, although progress has been made in reducing
disparities in incidence of new infections rates among
non-Hispanic blacks have declined, the incidence rates re-
main more than twofold higher than those among other
ethnic population and the rate in elderly immigrants is
much lower than in young adults, although the number of
elderly immigrants is very low. Several authors have
already analyzed the relationship between the incidence of
hepatitis B and immigration, showing that there is a posi-
tive relationship between both [23,24].
In 1992, the rate in females in Catalonia was 2 x10-5
person-years, which fell to 0.45 x10-5 person-years in
2000 and remained fairly stable in the remainder of the
study period. In the USA [22] the rate fell from 7.34 in
males and 5.01 in females (x10-5 person-years) in 1992
to 3.6 and 2.09 x 10-5 person-years, in males and
females, respectively, in 2000 and 1.85 in males and 1.15
in females (x10-5 person-years) in 2007, while in Germany,
rates fell from 1.96 x10-5 person-years in 2001 to 0.89 x10-5
person-years in 2006 and 0.6 x10-5 person-years in 2007.
In people aged 12-18 years, the incidence was zero in
2000 and less than one case per year, later. No gender
differences in the incidence were detected in indigenous
children of vaccination age or in children aged < 12 years,
with very low or zero rates. The rates in indigenous
women and people aged < 18 years were less than 1x10-5
person-years, as a result of the vaccination programs
implemented. In contrast, in immigrants and other age
groups, the reported incidence was more than two-fold
higher for men than for women.
The male-female ratio doubled over the study period,
unlike the results in the USA [22] and Germany [25]. In
the USA, the male-female ratio increased slightly, from1.5 in 1992 to 1.8 in 2006, and in Germany, it rose from
1.91 in 2001 to 2.2 in 2008. This may be explained by
the increased incidence in immigrants, a group contain-
ing a large proportion of men of working age. The statis-
tical models used show that the incidence of cases
increased due to immigration, especially in groups with >
15% of immigrants.
Although the impact of disease prevention measures
and the maintenance of high vaccination coverages are
important, this impact may be offset by an increase in
cases in adult immigrants. The proportion of immigrants
aged >50 years is still low, which could explain the low
incidence of acute hepatitis B in this population com-
pared to younger ages. Therefore, as suggested by the
distribution of cases in other countries [22,25], the inci-
dence may increase in these groups. For this reason, vac-
cination strategies for risk groups, including travellers to
countries with high or intermediate prevalence of chronic
Hepatitis B virus infection should be reinforced [26,27].
This recommendations should also be applicable to sus-
ceptible immigrants (children and adolescents) coming
from countries with high or intermediate prevalence where
hepatitis B vaccination programmes have still not been
launched or where coverages are still very low [28].
In countries like the USA, Germany and Italy, inci-
dence rates have declined in all age groups. In Germany,
the rate for males decreased from 2.8 x10-5 person-years
in 2001 to 1.2 x10-5 person-years in 2007, while in the
USA [22] the rate fell from 3.6 and 2.09 (x 10-5 person-
years) in 2000 to 1.85 and 1.15 (x10-5 person-years in
2007 in males and females, respectively. In Catalonia,
the rate increased from 1.3 x 10-5 person-years in 2001
to 2.9 x10-5 person-years in 2007. However, it should be
noted that, in Germany, the percentage of immigrants
has remained constant at around 9% since 1995 [25]. In
the USA the percentage of immigrants increased from
10.4% in 2000 to 12.6% in 2007 [29]. However, in Catalo-
nia, the rise was much higher, from 4.1% in 2000 to
15.7% in 2007.
This study was conducted using routine surveillance
data. It would probably be useful to focus more-closely
on immigrants and risk groups to obtain a better
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tion in order to design strategies to increase vaccination
coverages [21,30].
In addition to the protection afforded to individuals in
avoiding the risk of chronic liver diseases such as cirrho-
sis and hepatocellular carcinoma [31], a strategy focused
not only on universal vaccination of infants or preado-
lescents but on risk groups, and immigrants should be
considered because it takes into account the substantial
indirect effects of vaccination, as avoiding new infections
avoid the cases transmitted by them [32].
A possible limitation of this study is the underdetec-
tion of cases in the immigrant population. The attend-
ance of health services is free in Catalonia for all people
(indigenous and immigrants), but we do not know if
there are differences in the attendance to medical ser-
vices for acute hepatitis B. So, we cannot rule out some
underdetection of cases in immigrant population. In
order to improve our estimates we would need to im-
prove the surveillance of acute hepatitis B disease and to
know what level of completeness of reporting we have
for immigrant and indigenous population.
With respect to the quality of the proposed forecasts,
the randomness in the incidence pattern of the disease is
much lower than in males, making it much easier to pre-
dict the temporal disease evolution. However, the ran-
domness in the incidence is greater in males, depending,
amongst other factors, on age and disease outbreaks,
and therefore it is more difficult to predict its future
evolution. The observed incidence was lower than the
confidence intervals of the predictions, indicating a
change in the pattern of the evolution of the disease.
Future research might concentrate on extending the
proposed models to include the spatial-temporal distribu-
tion of the disease, as we have done for hepatitis A [33].
Likewise, Pearce and Dorling [34] studied a period of
rapid social, economic and political changes in which dif-
ferences in life expectancy between men and women had
a clear geographical dependence. It is essential that future
studies have access to more reliable information on immi-
gration and that they can recover missing data whenever
possible, in order to detect disease outbreaks earlier and
adjust the vaccination strategy to these situations.
Conclusions
In conclusion, the results of the models used in this
study confirm that the overall incidence of hepatitis B
has declined in Catalonia due to the universal vaccin-
ation of preadolescents, but that the incidence has
increased in male immigrants. Given the seriousness of
hepatitis B virus infection for individuals and for the
community, universal vaccination programmes should
be continued and measures to increase vaccination of
risk groups and immigrants, should be reinforced.Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
All the authors participated in the design, implementation and interpretation
of the study. MO and GC had full access to all the study data and take
responsibility for the data and accuracy of the data analysis, MO, MPM and
AD designed the study and drafted the report; EB and JB contributed to
obtain and supervised all information about vaccines, MO, MPM and NS
conducted the statistical analysis and contributed to editing the manuscript.
All authors read and approved the final manuscript.
Acknowledgments
This study was partially funded by CIBER Epidemiología y Salud Pública
(CIBERESP), Spain, FEDER and AGAUR (expedient number 2009 SGR 42). The
authors acknowledge financial support from grant MTM2008-03010. We
thank the reporting physicians and technicians of the Epidemiological
Surveillance Units of the Department of Health and Public Health Agency of
Barcelona.
Author details
1Department of Statistics and Operations Research, Universidade de Santiago
de Compostela (St. Lope Gómez de Marzoa, s/n. Campus sur), Santiago de
Compostela 15782, Spain. 2CIBER Epidemiología y Salud Pública (CIBERESP),
Melchor Fernández Almagro 3-5, Barcelona 28029, Spain. 3Department of
Statistics and Operations Research, Universitat Politècnica de Catalunya
(UPC), Jordi Girona, 1-3, Barcelona 08034, Spain. 4Agency of Public Health of
Catalonia, Roc Boronat 85, Barcelona 08005, Spain. 5Departament de Salut
Pública, Universitat de Barcelona, Casanova 143, Barcelona 08036, Spain.
Received: 6 September 2011 Accepted: 12 July 2012
Published: 6 August 2012
References
1. Mackie CO, Buxton JA, Tadwalkar S, Patrick DM: Hepatitis B immunization
strategies: timing is everything. Can Med J A 2009, 20:196–202.
2. Zanetti A, Van Damme P, Shouval D: The global impact of vaccination
against hepatitis B: A historical overview. Vaccine 2008,
26:6266–6273.
3. Piorkowsky NY: Europe’s hepatitis challenge: defusing the “viral bomb”.
J Hepatol 2009, 5:1068–1073.
4. Levy AR, Kowdley KV, lloeje U, Taffese E, Mukherjee J, Gish R, Bzowej N,
Briggs AH: The impact of chronic hepatitis B on quality of life: a
multinational study of utilities from infected and uninfected persons.
Value in Health 2008, 11:527–538.
5. Beutels P: Economic evaluations of hepatitis B immunization: a global
review of recent studies (1994–2000). Heal Econ 2001, 10:751–774.
6. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel M,
Ward JW: Recommendations for identification and public health
management of persons with chronic hepatitis B virus infection. MMWR
2008, 57(RR08):1–20.
7. World Health Organization: Viral hepatitis. Report by the Secretariat. Executive
Board. Geneva: WHO; 2009.
8. Salleras L, Bruguera JM, Vidal J, Taberner JL, Plans P, Bayas JM, Pumarola T,
Jimenez de Anta MT, Rodés J: Prevalence of hepatitis B markers in the
population of Catalonia (Spain) Rationale for universal vaccination of
adolescents. Eur J Epidemiol 1992, 8(5):640–644.
9. Lopalco PL, Salleras L, Barbuti S, Germinario C, Bruguera M, Buti M,
Domínguez A: Hepatitis A and B in children and adolescents – what can
we learn from Puglia (Italy) and Catalonia (Spain). Vaccine 2000,
19(4-5):470-–474.
10. Salleras L, Dominguez A, Bruguera M, Cardeñosa N, Batalla J, Carmona G,
Navas E, Taberner JL: Dramatic decline in acute hepatitis B infection and
disease incidence rates among adolescents and young people after
12 years of a mass hepatitis B vaccination programme of pre-adolescents
in the schools of Catalonia (Spain). Vaccine 2005, 23:2181–2184.
11. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS: A
mathematical model to estimate global hepatitis B disease burden and
vaccination impact. Int J Epidemiol 2005, 34:1329–1339.
12. La Torre G, Nicolotti N, de Waure C, Chiaradia G, Specchia ML, Mannocci A,
Ricciardi W: An assessment of the effect of hepatitis B vaccine in
decreasing the amount of hepatitis B disease in Italy. Virol J 2008, 5:84.
Oviedo et al. BMC Public Health 2012, 12:614 Page 12 of 12
http://www.biomedcentral.com/1471-2458/12/61413. Armstrong GL, Mast E, Wojczynski M, Margolis H: Childhood Hepatitis B
Virus Infections in the United States Before Hepatitis B Immunization.
Pediatrics 2001, 108:1123–1128.
14. Thornley S, Bullen C, Roberts M: Hepatitis B in a high prevalence New
Zealand population: a mathematical model applied to infection control
policy. J Theor Biol 2008, 254(3):599–603.
15. Institut d’Estadística de Catalunya (IDESCAT): Informació territorial: Banc
d’estadístiques de municipis i comarques. Idescat. 2007. http://www.idescat.
net/cat/poblacio/poblestructura.html.
16. Hastie TJ, Pregibon D: Generalized linear models. In Chapter 6 of Statistical
Models in S. Edited by Chambers JM, Hastie TJ. Boca Raton, FL:
Chapman&Hall/CRC; 1992:195–248.
17. Venables WN, Ripley BD: Modern Applied Statistics with S. New York:
Springer; 2002.
18. Hastie TJ, Tibshirani RJ: Generalized additive models. New York: Chapman and
Hill; 1990.
19. Oviedo M, Muñoz MP, Domínguez A, Borras E, Carmona G: A statistical
model to estimate the impact of a hepatitis A vaccination programme.
Vaccine 2008, 26:6157–6164.
20. Williamson JM, Lin HM, Lyles RH, Hightower AW: Power Calculations for
ZIP and ZIPNB. J Data Sci 2007, 5:519–534.
21. Kim WR: Epidemiology of hepatitis B in the United States. Hepatology
2009, 49:S28–S34.
22. Centers for Disease Control and Prevention (CDC): Viral Hepatitis Surveillance
– United States. 2009. http://www.cdc.gov/hepatitis/statistics/
2009surveillance/.
23. Raptopoulou M, Papatheodoridis G, Antoniou A, Ketikoglou J, Tzourmakliotis
D, Vastiladis T, Manolaki N, Nikolopoulou G, Manesis E, Pierroutsakos I:
Epidemiology, course and disease burden of chronic hepatitis B virus
infection. HEPNET study for chronic hepatitis B: a multicentre Greek
study. J Viral Hepat 2009, 16:195–202.
24. Buti M, Homs M, Rodriguez-Frias, Funalleras G, Jardí R, Sauleda S, Tabernero
D, Schaper M, Esteban R: Clinical outcome of acute and chronic hepatitis
delta over time: a long-term follow-up study. J Viral Hepat 2011,
18:434–442.
25. Federal Ministry of the Interior: Migration and Integration. Residence law and
policy on migration and integration in Germany. (http://www.zuwanderung.
de/EN/VeroeffDokumente/veroeffdokumente_node.html).
26. Mast EE, Weunbaum EE, Fiore AE, Alter MJ, Bell BP, Finelly L, Rodewald LE,
Douglas JM, Jansen RS, Ward JW: A comprehensive immunization strategy
to eliminate transmission of hepatitis B virus infection in the United
States. MMWR 2006, 55(RR16):1–25.
27. Centers for Disease Control and Prevention: Recommended adult
immunization schedule- United States, 2010. MMWR 2010, 59:1–4.
28. American Academy of Pediatrics: In 2009 Report of the Committee on
Infectious Diseases. 28th edition. Edited by Elk Grove. Village, IL: American
Academy of Pediatrics; 2009:337–356.
29. Census Bureau Homepage. 2010. www.census.gov.
30. Baldo V, Floreani A, Menegon T, Grella P, Paternoster DM, Trivello R:
Hepatitis C virus, hepatitis B virus and human immunodeficiency virus
infection in pregnant women in North-East Italy: A seroepidemiological
study. Eur J Epidemiol 2000, 16:87–91.
31. Perz JF, Elm JL, Fiore AE, Huggler JI, Kuhnert WL, Effler PV: Near elimination
of hepatitis B virus infections among Hawaii elementary school children
after universal infant hepatitis B vaccination. Pediatrics 2006,
118:1403–1408.
32. Kretzschmar M, Mangen MJ, van de Laar M, de Wit A: Model based
analysis of hepatitis B vaccination strategies in the Netherlands. Vaccine
2009, 27:1254–1260.
33. Oviedo M, Muñoz MP, Domínguez A, Carmona G, Batalla J, Borras E, Jansa
JM: Evaluation of mass vaccination programmes: the experience of
hepatitis A in Catalonia. Rev Esp Salud Pública 2009, 83:697–709.
34. Paerce J, Dorling D: Geographical inequalities in health in New Zealand,
1980–2001. Int J Epidemiol 2006, 35:597–603.
doi:10.1186/1471-2458-12-614
Cite this article as: Oviedo et al.: The impact of immigration and
vaccination in reducing the incidence of hepatitis B in Catalonia (Spain).
BMC Public Health 2012 12:614.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
